EPZICOM Drug Patent Profile

Which patents cover Epzicom, and what generic alternatives are available?

Epzicom is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in EPZICOM is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epzicom

A generic version of EPZICOM was approved as abacavir sulfate; lamivudine by CHARTWELL RX on March 28^th, 2017.

Summary for EPZICOM

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	21
Drug Prices:	Drug price information for EPZICOM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPZICOM
What excipients (inactive ingredients) are in EPZICOM?	EPZICOM excipients list
DailyMed Link:	EPZICOM at DailyMed

See drug prices for EPZICOM

Recent Clinical Trials for EPZICOM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme Corp.	Phase 3
AIDS Clinical Trials Group	Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3

See all EPZICOM clinical trials

Paragraph IV (Patent) Challenges for EPZICOM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPZICOM	Tablets	abacavir sulfate; lamivudine	600 mg/300 mg	021652	1	2007-09-27

US Patents and Regulatory Information for EPZICOM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004		DISCN	Yes	No

Expired US Patents for EPZICOM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004	5,034,394*PED
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004	6,294,540*PED
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004	7,119,202*PED
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004	5,047,407*PED
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004	6,180,639
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004	5,905,082*PED

International Patents for EPZICOM

When does loss-of-exclusivity occur for EPZICOM?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPZICOM around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	0382526
Israel	132793
European Patent Office	0479822	NUCLEOSIDES THERAPEUTIQUES (THERAPEUTIC NUCLEOSIDES)
Finland	906367
Japan	H08504212
Morocco	26498

Supplementary Protection Certificates for EPZICOM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0434450	990028	Netherlands		PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBAAR ESTER, IN HET BIJZONDER ABACAVIR SULFAAT; REGISTRATION NO/DATE: EU/1/99/112/001-002 19990708
0382526	19675032	Germany		PRODUCT NAME: LAMIVUDINE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH GEEIGNETEN SALZES; NAT. REGISTRATION NO/DATE: EU/1/96/015/001-002 19960808 FIRST REGISTRATION: CH 53662 53663 19960228
0434450	C990028	Netherlands		PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBAAR ESTER, IN HET BIJZONDER ABACAVIR SULFAAT; REGISTRATION NO/DATE: EU/1/99/112/001-002 19990708
0434450	1999C0033	Belgium		PRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628
0434450	SPC/GB99/032	United Kingdom		PRODUCT NAME: ABACAVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE INCLUDING ABACAVIR SULPHATE; REGISTERED: CH CH 55048 001 19990628; CH CH 55049 002 19990628; UK EU/1/99/112/001 19990708; UK EU/1/99/112/002 19990708
0817637	C300195	Netherlands		PRODUCT NAME: ABACAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDB AAR ZUURADDITIEZOUT, IN HET BIJZONDER HET HEMISULFAAT, EN LAMIV UDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; REGISTRTION NO/DATE: EU/04/298/001-002 20041217

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: EPZICOM

Last updated: January 17, 2026

Summary

EPZICOM (abacavir sulfate and lamivudine) is an antiretroviral medication primarily indicated for the treatment of HIV-1 infection. This analysis explores the current market landscape, competitive environment, regulatory considerations, revenue projections, and key drivers influencing its financial trajectory. By examining recent sales data, patent statuses, market penetration factors, and emerging trends such as generic entry and new formulation development, stakeholders can assess its growth potential and strategic positioning in the HIV therapeutics space.

---

What is EPZICOM and Its Therapeutic Profile?

Component	Purpose	Mechanism of Action
Abacavir sulfate	Reverse transcriptase inhibitor	Inhibits viral DNA synthesis
Lamivudine	Nucleoside reverse transcriptase inhibitor	Blocks reverse transcriptase enzyme

Indications:
EPZICOM is approved for the treatment of HIV-1 infection in combination with other antiretroviral agents, in adults and pediatric patients above 3 months who weigh at least 3 kg.

Formulations & Dosing:

• Fixed-dose combination tablet with once-daily dosing
• Available orally in 600 mg (abacavir) and 300 mg (lamivudine) doses

---

What Are the Market Dynamics Affecting EPZICOM?

1. Market Size and Demand Drivers

Parameter	Details	Implication
Global HIV Burden	Approx. 38 million people living with HIV globally (UNAIDS 2022)	Continuous demand for antiretroviral therapies
Key Markets	US, EU, emerging markets (Africa, Asia)	Influences sales concentration and growth potential
Treatment Penetration	Limited access in low-income regions; high in developed markets	Market expansion contingent upon access improvements

2. Competition and Patent Landscape

Agent	Status	Market Share	Notes
Epzicom (HIV)	Marketed since 2004	Estimated 10-15% in NRTIs segment	Competition with other fixed-dose combinations like Truvada, Descovy
Generic Abacavir + Lamivudine	Entry since patent expiry (2018-2020)	Growing, capturing off-patent market	Price competition increasing, impacting branded sales
Biktarvy (Bictegravir-based)	Market leader since 2018	25-30% in NRTI combinations	Higher efficacy and improved tolerability influence preference

3. Regulatory Environment & Patent Expiry

• Patents:
  The primary patent expired in 2018 in the U.S., opening pathways for generics.
• Regulations:
  Harmonization efforts (e.g., FDA, EMA, WHO) facilitate accelerated approval pathways for generics and biosimilars.

4. Pricing and Reimbursement Trends

Region	Pricing Trends	Reimbursement Policies
US	List price ~$1,200 per month (branded)	Payers increasingly favor generics; cost containment pressures
EU	Lower prices due to national negotiations	Access to generics enhances affordability
Emerging Markets	Significantly lower prices, often subsidized	Heavy reliance on international aid and government programs

---

What Is the Financial Trajectory for EPZICOM?

Historical Sales and Revenue Data

Year	Estimated Global Sales (USD Millions)	Notes
2015	Approx. 140	Peak branded sales, prior to generic entries
2018	Approx. 90	Decline following patent expiry, increase in generics
2020	Approx. 60	Market share shift toward generics
2022	Approx. 45	Continued decline, competition intensifies

Sources: Industry reports, IQVIA data, company disclosures.

Projection Scenarios (Next 5 Years)

Scenario	Estimated Revenue (USD Millions)	Key Factors
Optimistic	$60–80	Launch of new formulations, increased access in emerging markets
Base	$40–60	Generic market penetration stabilizes sales
Pessimistic	<$40	New competing therapies, regulatory hurdles, patent challenges

Potential Revenue Streams

• Original branded sales: Declining trend
• Generic sales: Growing, especially in mass markets
• Fixed-dose combination market: Competition from newer combinations
• Licensing and partnerships: Due to increased manufacturing and distribution channels

Cost and Margin Considerations

Cost Element	Estimate/Impact	Notes
R&D Investment	Moderate, limited for existing formulations	Focus on new formulations or combinations
Manufacturing Costs	Decreasing with generics	Economies of scale in generic manufacturing
Licensing & Patent Fees	Absent post-patent expiry	Cost savings with generic competition

---

What Market Trends Could Shape Future Growth?

Emerging Trends:

1. Introduction of Fixed-Dose Combinations (FDCs):

   • Simplify regimens to enhance adherence
   • Competition with newer FDCs like Biktarvy, Truvada

2. Generic and Biosimilar Entries:

   • Magnify pricing pressure and market share shifts
   • U.S. FDA and EMA approvals facilitate faster generic entry

3. Development of Long-Acting Injectables:

   • Potentially disrupt oral therapies by improving adherence
   • Examples include Cabotegravir and Rilpivirine long-acting formulations

4. Market Expansion in Low-Income Countries:

   • Driven by global health initiatives and subsidies (PEPFAR, Global Fund)
   • Generics dominate in these territories, reducing branded revenues

---

How Does EPZICOM Compare with Its Competitors?

Parameter	EPZICOM (Brand)	Truvada (Gilead)	Biktarvy (Gilead)	Descovy (Gilead)
Approval Year	2004	2004	2018	2016
Formulation	Fixed-dose oral tablet	Fixed-dose oral tablet	Fixed-dose oral tablet	Fixed-dose oral tablet
Market Share (2022)	10-15%	25-30%	25-30%	10-15%
Pricing (USD per month)	~$1,200	$2,000+	$1,300+	~$1,300
Patent Status	Expired in key markets	Active patent until 2023/2024	Patent till at least 2028	Patent till at least 2028

---

What Are the Key Challenges and Opportunities?

Challenges

• Decreasing patent protections leading to erosion of revenue
• Competitive pressure from generics and newer therapies
• Pricing pressures in price-sensitive markets
• Risk of adverse events influencing prescribing trends (e.g., hypersensitivity reactions with abacavir)

Opportunities

• Launch of novel formulations (e.g., fixed-dose combinations with newer agents)
• Expanding access in emerging markets facilitated by cost reductions
• Potential for combination with long-acting injectables
• Strategic licensing and co-marketing agreements

---

Final Analysis: What Is the Future Outlook for EPZICOM?

EPZICOM’s future hinges on market positioning post-patent expiry, evolving treatment paradigms, and global access initiatives. The decline in sales of branded formulations is expected to continue, supplanted by cheaper generics and competing newer agents. Nevertheless, opportunities exist in niche markets, combination therapies, and emerging markets where access barriers persist.

Long-term growth may be achievable through strategic innovation, diversification, and partnerships, particularly in the context of evolving HIV treatment standards emphasizing adherence and tolerability.

---

Key Takeaways

• EPZICOM has seen declining revenues since patent expiry due to increased generic competition.
• The global HIV treatment market remains sizable, yet price sensitivity and regulatory shifts are pressuring margins.
• The rise of fixed-dose combinations and long-acting injectables will influence its market share.
• Success will depend on adaptation strategies including formulation innovation, market expansion, and collaborating on combination therapies.
• Competitive and regulatory landscapes continue to evolve, demanding agile responses from stakeholders.

---

FAQs

1. How does patent expiry affect EPZICOM’s market position?

Patent expiry in 2018 allowed generic manufacturers to enter the market, significantly reducing branded sales and intensifying price competition.

2. What are the main competitors of EPZICOM in the HIV therapeutics market?

Key competitors include Gilead’s Truvada, Descovy, and Biktarvy, as well as generic combinations of abacavir and lamivudine.

3. Is EPZICOM still the preferred choice for HIV treatment?

In most developed markets, newer formulations with better efficacy, tolerability, and adherence profiles have overshadowed EPZICOM, relegating it to lower-tier options.

4. What factors could enable EPZICOM to rebound or sustain market relevance?

Innovations such as long-acting formulations, strategic licensing, and targeted use in niche populations could support its ongoing relevance.

5. What policies can impact EPZICOM’s future sales?

Pricing regulations, reimbursement policies, and approval processes for generics/biosimilars will heavily influence market dynamics.

---

References

[1] UNAIDS. Global HIV & AIDS statistics — 2022 fact sheet.
[2] IQVIA. Global Trends in HIV Antiretroviral market, 2022.
[3] U.S. Food & Drug Administration. Patent and exclusivity information for HIV drugs, 2018-2022.
[4] Gilead Sciences Annual Reports, 2015–2022.
[5] WHO. Global policy on HIV treatment adherence and access, 2021.

Note: All data is based on industry reports, public disclosures, and market analyses as of early 2023.